Title Why We Need an Alzheimer’s Moonshot in 2022 2022-05-01

Why We Need an Alzheimer’s Moonshot in 2022

Genuv calls for an urgent, all-hands-on-deck drug development effort to ameliorate the fast-worsening health crisis that is Alzheimer’s disease

By Sungho Han, PhD, and Allan I. Levey, MD, PhD


When science changes, it often takes a long time for nonscientists to catch up.

The prevailing belief for many decades was that humans are born with a fixed number of brain cells, or neurons, and those hardy cells needed to last a lifetime. But many would unfortunately be lost prematurely due to the use of alcohol and participation in violent sports.


To view original article, please click here.

Prev Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June 2022
Next Next-gen IL-2 GNUV204, selected by the Korean government for a development grant